Menu Search
Equities

Crinetics Pharmaceuticals Inc

6Z4:BER

Crinetics Pharmaceuticals Inc

Actions
  • Price (EUR)53.50
  • Today's Change-0.50 / -0.93%
  • Shares traded22.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 19:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Crinetics Pharmaceuticals Inc's revenues fell -15.28% from 4.74m to 4.01m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 163.92m to a larger loss of 214.53m.
Gross margin--
Net profit margin-26,298.27%
Operating margin-29,525.22%
Return on assets-34.61%
Return on equity-40.26%
Return on investment-36.80%
More ▼

Cash flow in USDView more

In 2023, Crinetics Pharmaceuticals Inc increased its cash reserves by 65.42%, or 22.22m. Cash Flow from Financing totalled 388.94m or 9,692.10% of revenues. In addition the company used 166.31m for operations while cash used for investing totalled 200.41m.
Cash flow per share-3.63
Price/Cash flow per share--
Book value per share10.30
Tangible book value per share10.30
More ▼

Balance sheet in USDView more

Crinetics Pharmaceuticals Inc uses little or no debt in its capital structure.
Current ratio16.38
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.